髙橋和久 医師 （たかはしかずひさ）

髙橋和久医師は、呼吸器内科一般を専門とし、肺がん、中皮腫だけでなく、アレルギー疾患、感染症、間質性肺炎など幅広い呼吸器系の疾患のスペシャリストである。がんの中で最も死亡率が高く治りにくいとされる肺がん治療にあえて挑みたいと肺がんの治療医師を志したと言う。
また、髙橋医師は、日本で初めて開設した最も古い歴史を有する呼吸器内科専門教室で2005年8月から主任教授として教室の運営にもあたっており、教育や育成、研究に力を入れている。2019年からは順天堂大学医学部附属順天堂医院院長を併任し、病院運営にも関わっている。中国の複数の大学の教授も併任している。
主な研究テーマには、抗がん剤や分子標的薬など、薬剤の耐性機序の解明と克服。薬が効かなくなった患者さんに効く薬を生む「創薬」をめざす。

原則として他の医療機関からの紹介状(診療情報提供書)が必要。紹介状がない場合は、初診時選定療養費として別途費用が必要となる。

1960年　東京都生まれ
1985年　順天堂大学医学部卒業
1994年～1997年　米国ハーバード大学医学部附属マサチューセッツ総合病院 腫瘍外科学留学 ポスドク
2003年　順天堂大学医学部呼吸器内科学講座助教授、順天堂大学大学院医学研究科呼吸器内科学助教授併任
2005年　順天堂大学医学部呼吸器内科学講座教授、順天堂大学大学院医学研究科呼吸器内科学教授併任
2014年　順天堂大学医学部附属順天堂医院　副院長
2019年　順天堂大学医学部附属順天堂医院　院長
2019年　西安交通大学第二附属医院（西北医院）特別栄誉教授
2020年　北京大学客員教授
2021年　中国医科大学客員教授
2024年4月～　順天堂大学大学院医学研究科長・順天堂大学医学部長

日本内科学会(評議員2012.4.14～/日本内科学会雑誌主任編集長2021.4～)
日本呼吸器学会(理事長 2024.4.1～、常務理事 2018.4.26～/理事2008.6.14～/代議員、第63回日本呼吸器学会学術講演会会長(2023年))
日本肺癌学会(常任理事、理事2012.11.10～/評議員/保険委員会委員長/第66回日本肺癌学会学術集会会長(2025年))
日本癌学会
日本臨床腫瘍学会(評議員)
日本サルコイドーシス/肉芽腫性疾患学会(理事/評議員)
日本呼吸器内視鏡学会(代議員/気管支鏡専門医制度委員会委員)
日本呼吸器内視鏡学会関東部会(幹事)
日本肺癌学会関東部会(幹事)
日本老年医学会(代議員)
日本呼吸ケア・リハビリテーション学会(代議員)
日本免疫学会
日本アレルギー学会
ATS(米国胸部学会)会員
ASCO(米国臨床腫瘍学会)正会員
APTA（アジア太平洋胸部疾患協会）代表理事
APSR(Asia Pacific Society of Respirology) 理事
IASLC(国際肺癌学会)会員

【受賞歴】
2002年　順天堂大学医学部同窓会学術奨励賞
2014年　APSR Harasawa Research Award
2017年　東京都医師会功労賞
2021年　日本医師会優功賞

世界で一番やさしい　肺がん(知ってなおすシリーズ)　高橋和久著　発行/エクスナレッジ
呼吸器内科　診療マニュアル　高橋和久、熱田了編集　日本医学館
講義録　腫瘍学　高橋和久編集　メジカルビュー社
EBMを活かす呼吸器診療　高橋和久、児玉裕三編集　メジカルビュー社
がんサポート　肺がん特集&リハビリテーション2015年9月号　エビデンス社
など多数

【論文】2024年1月-2025年4月までの英文原著論文のみ
1.Yoshikawa H, Sato T, Horikoshi K, Komura M, Arano Nitta N, Mitsui A, Koike K, Kodama Y, Takahashi　K. miR-146a regulates emphysema formation and abnormal inflammation in the lungs of two mouse models. Am J Physiol Lung Cell Mol Physiol. 326(1): L98-L110, 2024 Jan

2.Sasano H, Harada N, Harada S, Takeshige T, Sandhu Y, Tanabe Y, Ishimori A, Matsuno K, Nagaoka T, Ito J, Chiba A, Akiba H, Atsuta R, Izuhara K, Miyake S, Takahashi　K. Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics. Allergol Int. 73(1): 94-106, 2024 Jan

3.Matsuno K, Asaoka D, Sugano K, Takahashi　K, Miyauchi K. Rationale and design of Juntendo Sarcopenia Registration to explore the predictors and prognosis of sarcopenia and frailty in the elderly in TOKYO (JUSTICE-TOKYO). Geriatr Gerontol Int. 24(1):168-172, 2024 Jan

4.Suzuki Y, Nagaoka T, Terayama Y, Nagata Y, Yoshida T, Tsutsumi T, Kuriyama S, Matsushita M, Joki Y, Takasu K, Konishi H, Takahashi　K. Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease. Respir Investig. 62(1):167-175, 2024 Jan

5.Yasuda M, Tobino K, Harada N, Ooi R, Sueyasu T, Nishizawa S, Munechika M, Yoshimine K, Ko Y, Yoshimatsu Y, Tsuruno K, Ide H, Takahashi　K. The prevalence of obstructive sleep apnea in Japanese asthma patients. Allergy Asthma Clin Immunol. 20(1):10, 2024 Feb

6.Nishioki T, Sato T, Okajima A, Motomura H, Takeshige T, Watanabe J, Yae T, Koyama R, Kido K, Takahashi　K. Impact of the COVID-19 pandemic on COPD exacerbations in Japanese patients: a retrospective study. Sci Rep 14(1): 2792, 2024 Feb　

7.Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi　K, Ikeda N, Tanahashi M, Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. Mol Oncol. 18(2):305-316, 2024 Feb

8.Torasawa M, Horinouchi H, Nomura S, Igawa S, Asai M, Ishii H, Wakui H, Ushio R, Asao T, Namba Y, Koyama R, Hayakawa D, Katayama I, Matsuda H, Sasaki S, Takahashi　K, Hosomi Y, Naoki K, Ohe Y. Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy. J Thorac Oncol. 19(2):325-336, 2024 Feb

9.Matsubara Y, Kiyohara H, Mikami Y, Nanki K, Namkoong H, Chubachi S, Tanaka H, Azekawa S, Sugimoto S, Yoshimatsu Y, Sujino T, Takabayashi K, Hosoe N, Sato T, Ishii M, Hasegawa N, Okada Y, Koike R, Kitagawa Y, Kimura A, Imoto S, Miyano S, Ogawa S, Fukunaga K, Kanai T; Japan COVID-19 Task Force. Gastrointestinal symptoms in COVID-19 and disease severity: a Japanese registry-based retrospective cohort study. J Gastroenterol. 59(3):195-208, 2024 Mar

10.Shirai Y, Ueno T, Kojima S, Ikeuchi H, Kitada R, Koyama T, Takahashi F, Takahashi　K, Ichimura K, Yoshida A, Sugino H, Mano H, Narita Y, Takahashi M, Kohsaka S. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma. J Neurooncol. 167(1):75-88, 2024 Mar

11.Kinoshita S, Ishii M, Ando J, Kimura T, Yamaguchi T, Harada S, Takahashi F, Nakashima K, Nakazawa Y, Yamazaki S, Ohshima K, Takahashi　K, Nakauchi H, Ando M. Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. Cancer Res Commun. 4(3):723-737, 2024 Mar

12.Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Tabe Y, Naito T, Takahashi K, Hattori K, Heissig B. Urokinase-type plasminogen activator and plasminogen Takeshige activator inhibitor-1 complex as a serum biomarker for COVID-19. Front Immunol. 2024 Mar 13;15:1390698. doi: 10.3389/fimmu.2024.1390698.

13.Aoki A, Iwamura C, Kiuchi M, Tsuji K, Sasaki A, Hishiya T, Hirasawa R, Kokubo K, Kuriyama S, Onodera A, Shimada T, Nagaoka T, Ishikawa S, Kojima A, Mito H, Hase R, Kasahara Y, Kuriyama N, Nakamura S, Urushibara T, Kaneda S, Sakao S, Nishida O, Takahashi　K, Kimura MY, Motohashi S, Igari H, Ikehara Y, Nakajima H, Suzuki T, Hanaoka H, Nakada TA, Kikuchi T, Nakayama T, Yokote K, Hirahara K. Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients. J Clin Immunol. 44(4):104, 2024 Apr

14.Abe S, Yasuda M, Tobino K, Harada S, Sasano H, Tanabe Y, Sandhu Y, Takeshige T, Matsuno K, Asao T, Sueyasu T, Nishizawa S, Yoshimine K, Ko Y, Yoshimatsu Y, Tsuruno K, Ide H, Takagi H, Ito J, Nagaoka T, Harada N, Takahashi　K. Usefulness of Computed Tomography for Evaluating the Effects of Bronchial Thermoplasty in Japanese Patients with Severe Asthma. J Asthma Allergy.17:325-337, 2024 Apr

15.Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi　K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy. Sci Rep. 14(1):10162, 2024 May

16.Kurokawa K, Asao T, Hayashi T, Kishikawa S, Kanamori K, Shukuya T, Miyashita Y, Nakamura I, Miyawaki T, Kanemaru R, Mimori T, Mitsuishi Y, Tajima K, Shimada N, Takahashi F, Takamochi K, Suzuki K, Takahashi　K. Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report. JTO Clin Res Rep. 2024 May 29;5(7):100693. doi: 10.1016/j.jtocrr.2024.100693.

17.Ogiwara M, Ihara H, Muto Y, Haba M, Nakazawa H, Hotta S, Jo H, Hayama N, Honma Y, Hoshi S, Fujii M, Takahashi　K. The Inciting Factor for Bradycardia in COVID-19 Patients: A Potential Harm of Steroid Treatment. J Thorac Dis. 16(5):2835-2844, 2024 May

18.Sato Y, Nishino K, Koike K, Shiozaki H, Kastu K, Murashima R, Nakazawa S，Masui Y, Shukuya T, Sekiya M, Hayashi T, Suzuki K, Takahashi　K. Thymoma extends into superior vena cava through the small blood vessel. Journal of Hospital General Medicine. 6(3): 81-82, 2024 May

19.Sonehara K, Yano Y, Naito T, Goto S, Yoshihara H, Otani T, Ozawa F, Kitaori T; Biobank Japan Project; Matsuda K, Nishiyama T, Okada Y, Sugiura-Ogasawara M. Common and rare genetic variants predisposing females to unexplained recurrent pregnancy loss. Nat Commun. 15(1):5744, 2024 Jul

20.Kato Y, Ihara H, Takei S, Nakamura A, Fujimoto Y, Handoh T, Kurokawa K, Arai Y, Shibayama K, Sumiyoshi I, Ochi Y, Watanabe J, Hoshi K, Misawa S, Togo S, Naito T, Tabe Y, Miida T and Takahashi　K. Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. IF:1.9 J Clin Tuberc Other Mycobact Dis. 2024 Jul 15:36:100464. doi: 10.1016/j.jctube.2024.100464.

21.Ihara H, Kondo K, Muto Y, Haba M, Nakazawa H, Handoh T, Arai Y, Shibayama K, Sumiyoshi I, Ochi Y, Watanabe J, Takei S, Nakamura A, Fujimoto Y, Togo S, Takahashi　K. The epidemiology of pulmonary Mycobacterium abscessus species in Japanese population. J Infect Chemother. 30(8):757-767, 2024 Aug

22.Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi　K. Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests. J Natl Compr Canc Netw. 2024 Aug 8;22(7): e247021.

23.Hikino K, Koyama S, Ito K, Koike Y, Koido M, Matsumura T, Kurosawa R, Tomizuka K, Ito S, Liu X, Ishikawa Y, Momozawa Y, Morisaki T, Kamatani Y, Mushiroda T, Terao C; Biobank Japan Project. RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction. JAMA Cardiol. 9(8):723-731, 2024 Aug

24.Hosaka Y, Yan Y, Naito T, Oyama R, Tsuchiya K, Yamamoto N, Nojiri S, Hori S, Takahashi K, Tabe Y. SARS-CoV-2 evolution among patients with immunosuppression in a nosocomial cluster of a Japanese medical center during the Delta (AY.29 sublineage) surge. Front Microbiol. 2024 Aug 23:15:1478638.　
doi: 10.3389/fmicb.2024.1478638. eCollection 2024.

25.Asao T, Shukuya T, Uemura K, Kitadai R, Yamamoto G, Mouri A, Tamaoka M, Imai R, Tsukita Y, Isobe K, Watanabe S, Kamimura M, Morita R, Kudo K, Inomata M, Tateishi K, Kakinuma K, Yoshioka H, Namba Y, Sumiyoshi I, Nakagawa T, Watanabe K, Kobayashi K, Takahashi K.　Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung Cancer. 2024 Aug;194:107894. doi: 10.1016/j.lungcan.2024.107894.

26.Tomofuji Y, Edahiro R, Sonehara K, Shirai Y, Kock KH, Wang QS, Namba S, Moody J, Ando Y, Suzuki A, Yata T, Ogawa K, Naito T, Namkoong H, Xuan Lin QX, Buyamin EV, Tan LM, Sonthalia R, Han KY, Tanaka H, Lee H; Asian Immune Diversity Atlas (AIDA) Network; Japan COVID-19 Task Force; Biobank Japan Project; Okuno T, Liu B, Matsuda K, Fukunaga K, Mochizuki H, Park WY, Yamamoto K, Hon CC, Shin JW, Prabhakar S, Kumanogoh A, Okada Y. Quantification of escape from X chromosome inactivation with single-cell omics data reveals heterogeneity across cell types and tissues. Cell Genom. 2024 Aug 14;4(8):100625.

27.Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Adachi E, Tabe Y, Hattori N, Osada T, Naito T, Takahashi K, Hattori K, Heissig B. The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction. Front Immunol. 2024 Aug 30;15:1445294.

28.Matsumoto N, Tajima K, Takahashi F, Mitsuishi Y, Wirawan A, Hidayat M, Winardi W, Wibowo A, Hayakawa D, Izumi K, Kanamori K, Miyashita Y, Handa T, Asao T, Ko R, Shukuya T, Shimada N, Takamochi K, Hayashi T, Suzuki K, Takahashi　K. Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancer. Respir Investig. 2024 Sep;62(5):901-909.

29.Torasawa M, Shukuya T, Uemura K, Hayashi T, Ueno T, Kohsaka S, Masui Y, Shirai Y, Okura M, Asao T, Mitsuishi Y, Shimada N, Takahashi F, Takamochi K, Suzuki K, Takahashi K, Seyama K. Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study. Respirology. 29(9):815-824, 2024 Sep

30.Harada S, Harada N, Sasano H, Tanabe Y, Kotajima M, Sato Y, Takeshige T, Katsura Y, Ito J, Atsuta R, Kurosawa H, Takahashi　K. Differences between oscillometry measurements obtained by MostGraph-01 and MasterScreen-IOS in patients with asthma. PLoS One. 19(9):e0309981, 2024 Sep

31.Masui Y, Shukuya T, Kataoka S, Shiozaki H, Kurokawa K, Nakamura I, Miyawaki T, Koinuma Y, Asao T, Kanemaru R, Shimamura SS, Mimori T, Mitsuishi Y, Tajima K, Shimada N, Takahashi K. Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy. Thorac Cancer. 2024 Nov;15(32):2291-2297. doi: 10.1111/1759-7714.15457.

32.Sato Y, Sasano H, Abe S, Sandhu Y, Ueda S, Harada S, Tanabe Y, Shima K, Kuwano T, Uehara Y, Inoue T, Okumura K, Takahashi　K, Harada N. Impact of Dupilumab on Skin Surface Lipid-RNA Profile in Severe Asthmatic Patients. Curr Issues Mol Biol. 46:11425-37, 2024 Oct

33.Abe S, Harada N, Sandhu Y, Sasano H, Tanabe Y, Ueda S, Nishimaki T, Sato Y, Takeshige T, Harada S, Akiba H, Takahashi　K. Co-Stimulation with TWEAK and TGF-β1 Induces Steroid-Insensitive TSLP and CCL5 Production in BEAS-2B Human Bronchial Epithelial Cells. Int J Mol Sci. 25(21):11625, 2024 Oct

34.Koinuma Y, Mitsuishi Y, Winardi W, Hidayat M, Wirawan A, Hayakawa D, Kanamori K, Matsumoto N, Hayashi T, Shimada N, Tajima K, Takamochi K, Takahashi F, Suzuki K, Takahashi K. Anti-Müllerian hormone type II receptor protein expression in non-small cell lung cancer and the effect of AMH/AMHR2 signaling on cancer cell proliferationThorac Cancer. 2024 Oct;15(29):2090-2099. doi: 10.1111/1759-7714.15309.

35.Matsumoto N, Yokokawa H, Mori H, Hiki M, Tabe Y, Takahashi K, Naito T. Association Between Serum Zinc Concentration Levels And Severity Of Coronavirus Disease 2019 (Covid-19) In Japanese InpatientsInt J Gen Med. 2024 Oct 16;17:4745-4753. doi: 10.2147/IJGM.S476578. eCollection 2024.　PMID: 39429954

36.Yagishita S, Yamanaka Y, Kurata T, Watanabe K, Hosomi Y, Horinouchi H, Ohe Y, Nakahara Y, Naoki K, Asao T, Takahashi K, Saeki S, Sakagami T, Nakashima K, Tsubata Y, Fujita Y, Wakui H, Furuta M, Konishi JS, Ohuchi M, Ando Y, Mizugaki H, Hamada A. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clin Pharmacol Ther. 2024 Oct;116(4):1042-1051. doi: 10.1002/cpt.3339.

37.Paran FJ, Oyama R, Khasawneh A, Ai T, Ismanto HS, Sherif AA, Saputri DS, Ono C, Saita M, Takei S, Horiuchi Y, Yagi K, Matsuura Y, Okazaki Y, Takahashi K, Standley DM, Tabe Y, Naito T. BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis. Front Immunol. 2024 Oct 28;
15:1405013. doi: 10.3389/fimmu.2024.1405013.

38.Akiyama M, Tamiya G, Fujiwara K, Shiga Y, Yokoyama Y, Hashimoto K, Sato M, Sato K, Narita A, Hashimoto S, Ueda E, Furuta Y, Hata J, Miyake M, Ikeda HO, Suda K, Numa S, Mori Y, Morino K, Murakami Y, Shimokawa S, Nakamura S, Yawata N, Fujisawa K, Yamana S, Mori K, Ikeda Y, Miyata K, Mori K, Ogino K, Koyanagi Y, Kamatani Y; Biobank Japan Project; Ninomiya T, Sonoda KH, Nakazawa T; Japan Glaucoma Society Omics Group; Genomic Research Committee of the Japanese Ophthalmological Society. Genetic Risk Stratification of Primary Open-Angle Glaucoma in Japanese Individuals. Ophthalmology. 2024 Nov;131(11):1271-1280. doi: 10.1016/j.ophtha.2024.05.026. Epub 2024 Jul 17. PMID: 39023470

39.Harada S, Sasano H, Ueda S, Sandhu Y, Abe S, Tanabe Y, Shima K, Kuwano T, Uehara Y, Inoue T, Okumura K, Takahashi　K, Harada N. Skin surface lipid-RNA profile obtained from patients with severe asthma after benralizumab treatment. J Asthma Allergy. 17:1103-1113, 2024 Nov

40.Yamamoto K, Namba S, Sonehara K, Suzuki K, Sakaue S, Cooke NP, Higashiue S, Kobayashi S, Afuso H, Matsuura K, Mitsumoto Y, Fujita Y, Tokuda T; Biobank Japan Project; Matsuda K, Gakuhari T, Yamauchi T, Kadowaki T, Nakagome S, Okada Y. Genetic legacy of ancient hunter-gatherer Jomon in Japanese populations. Nat Commun. 2024 Nov 12;15(1):9780. doi: 10.1038/s41467-024-54052-0.　PMID: 39532881

41.Goto A, Harada S, Sasano H, Sandhu Y. Tanabe Y, Abe S, Ueda S, Takeshige T, Matsuno K, Nagaoka T, Ito J, Atsuta R, Takahashi　K, Harada N. Japanese patients with severe asthma identified as responders to omalizumab treatment at 2 years based on the GETE score continued treatment for an extended period. J Asthma Allergy. J Asthma Allergy. 2024 Nov 14;17:1173-1186. doi: 10.2147/JAA.S423256. eCollection 2024.
PMID: 39558969

42.Hoshi K, Hashim Y, Togo S, Saiwaki S, Motomura H, Sumiyoshi I, Nakazawa S, Ochi Y, Miyoshi C, Heo R, Tabe Y, Abe K, Urata Y, Takahashi K. Design of buffer property for the new enrichment method of circulating tumor cell based on immunomagnetic-negative separation. Comput Struct Biotechnol J. 2024 Nov 26;25:281-289. doi: 10.1016/j.csbj.2024.11.033. eCollection 2024 Dec. PMID: 39720309

43.Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, Watanabe S, Tanaka H, Hirata A, Hakozaki T, Hamai K, Matsumoto N, Watanabe K, Ashinuma H, Miyauchi E, Sugano K, Hosokawa S, Amano K, Morita S, Kobayashi K, Maemonodo M, Takahashi K. Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A. J Cachexia Sarcopenia Muscle. J Cachexia Sarcopenia Muscle. 15(6):2618-2628, 2024 Dec

44.Flanagan J, Liu X, Ortega-Reyes D, Tomizuka K, Matoba N, Akiyama M, Koido M, Ishigaki K, Ashikawa K, Takata S, Shi M, Aoi T, Momozawa Y, Ito K, Murakami Y, Matsuda K; Biobank Japan Project; Kamatani Y, Morris AP, Horikoshi M, Terao C. Population-specific reference panel improves imputation quality for genome-wide association studies conducted on the Japanese population. Commun Biol. 2024 Dec 19;7(1):1665. doi: 10.1038/s42003-024-07338-4.　PMID: 39702642

45.Yan Y, Ito K, Fukuda H, Nojiri S, Urasaki W, Yamamoto T, Horiuchi Y, Hori S, Takahashi K, Naito T, Tabe Y. SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020-2023. Hum Vaccin Immunother. 2024 Dec 31;20(1):2337984. doi: 10.1080/21645515.2024.2337984.

46.Nishimaki T, Sasano H, Harada S, Takeshige T, Sandhu Y, Tanabe Y, Matsuno K, Nagaoka T, Ito J, Atsuta R, Ohuchi M, Yagishita S, Hamada A, Takahashi K, Harada N. Elevated mepolizumab levels in patients with severe asthma responsive to 1 year's mepolizumab treatmentJ Allergy Clin Immunol Glob. 2025 Jan 16;4(2):100410.

47.Mizumura K, Gon Y, Harada N, Yamada S, Fukuda A, Ozoe R, Maruoka S, Abe S, Takahashi K, Tanaka A, Sagara H, Akamatsu T, Shirai T, Masaki K, Fukunaga K, Kobayashi K, Nagase H, Miyahara N, Kanehiro A, Kitamura N, Sugihara N, Kumasawa F, Terada-Hirashima J, Hojo M, Chibana K, Tagaya E.　Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma. Allergol Int. 2025 Jan; 74(1):144-155. doi: 10.1016/j.alit.2024.08.005.

48.Sasa N, Kojima S, Koide R, Hasegawa T, Namkoong H, Hirota T, Watanabe R, Nakamura Y, Oguro-Igashira E, Ogawa K, Yata T, Sonehara K, Yamamoto K, Kishikawa T, Sakaue S, Edahiro R, Shirai Y, Maeda Y, Nii T, Chubachi S, Tanaka H, Yabukami H, Suzuki A, Nakajima K, Arase N, Okamoto T, Nishikawa R, Namba S, Naito T, Miyagawa I, Tanaka H, Ueno M, Ishitsuka Y, Furuta J, Kunimoto K, Kajihara I, Fukushima S, Miyachi H, Matsue H, Kamata M, Momose M, Bito T, Nagai H, Ikeda T, Horikawa T, Adachi A, Matsubara T, Ikumi K, Nishida E, Nakagawa I, Yagita-Sakamaki M, Yoshimura M, Ohshima S, Kinoshita M, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Uchida A, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Saigusa M, Shirai T, Hizawa N, Nakata K; Japan COVID-19 Task Force; Imafuku S, Tada Y, Asano Y, Sato S, Nishigori C, Jinnin M, Ihn H, Asahina A, Saeki H, Kawamura T, Shimada S, Katayama I, Poisner HM, Mack TM, Bick AG, Higasa K, Okuno T, Mochizuki H, Ishii M, Koike R, Kimura A, Noguchi E, Sano S, Inohara H, Fujimoto M, Inoue Y, Yamaguchi E, Ogawa S, Kanai T, Morita　A, Matsuda F, Tamari M, Kumanogoh A, Tanaka Y, Ohmura K, Fukunaga　K, Imoto S, Miyano S, Parrish　NF, Okada　Y. Blood DNA virome associates with autoimmune diseases and COVID-19. Nat Genet. 2025 Jan;57(1):65-79. doi: 10.1038/s41588-024-02022-z. Epub 2025 Jan 3. PMID: 39753770

49.Harada S, Kato M, Nakagome K, Sasano H, Tanabe Y, Takeshige T, Sandhu Y, Matsuno K, Ueda S, Abe S, Nishimaki T, Shinomiya S, Ito J, Miyake S, Okumura K, Nagata M, Takahashi K, Harada N. Evaluating the Diagnostic Value of Lymphocyte Subsets in Bronchoalveolar Lavage Fluid and Peripheral Blood Across Various Diffuse Interstitial Lung Disease Subtypes. Biomolecules. 2025 Jan 14;15(1):122. doi: 10.3390/biom15010122.

50.Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Seike M, Takahashi K, Yamamoto N, Yotsukura M, Watanabe SI, Shintani Y. Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry databaseLung Cancer. 2025 Feb;200:108102. doi: 10.1016/j.lungcan.2025.108102. Epub 2025 Jan 19. PMID: 39924255

51.Ohyama N, Matsunami M, Imamura M, Yoshida A, Javed A, Liu X, Kimura R, Matsuda K; BioBank Japan Project; Terao C, Maeda S. A variant in HMMR/HMMR-AS1 is associated with serum alanine aminotransferase levels in the Ryukyu populationSci Rep. 2025 Feb 22;15(1):6494. doi: 10.1038/s41598-025-90195-w. PMID: 39987337

52.Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, Tanaka H, Ko R, Amano Y, Tachihara M, Suzuki T, Tanizaki J, Sugawara S, Zenke Y, Shirai Y, Hayashi T, Mori K, Takahashi K.　Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025 Mar;26(3):331-342. doi: 10.1016/S1470-2045(25)00001-4.　PMID: 40049197

53.Miyashita Y, Tajima K, Izumi K, Matsumoto N, Hayakawa D, Nakamura IT, Katayama I, Wibowo A, Matsuda H, Winardi W, Amien BR, Mitsuishi Y, Takahashi F, Nakamura K, Uchibori K, Yanagitani N, Hayashi T, Takamochi K, Suzuki K, Katayama R, Takahashi K. Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors. Cancer Sci. 2025 Mar 4. doi: 10.1111/cas.70032. Online ahead of print. PMID: 40036147

54.Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, Miyakoshi J, Tateishi A, Igawa YS, Higashiyama RI, Mochizuki A, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Takahashi K, Kohno T, Ohe Y. Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma. Lung Cancer. Lung Cancer. 2025 Apr;202:108494.